The following are the top rated Health Care stocks according to Validea's Growth Investor model based on the published strategy of Martin Zweig. This strategy looks for growth stocks with persistent accelerating earnings and sales growth, reasonable valuations and low debt.
CARDINAL HEALTH INC (CAH) is a large-cap growth stock in the Major Drugs industry. The rating according to our strategy based on Martin Zweig is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Cardinal Health, Inc. is a global healthcare services and products company. The Company is engaged in providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices and patients in the home. The Company also provides pharmaceuticals and medical products. The Companys segments include Pharmaceutical and Specialty Solutions and Global Medical Products and Distribution (GMPD). The Pharmaceutical and Specialty Solutions segment distributes branded and generic pharmaceuticals, specialty pharmaceuticals and over-the-counter healthcare and consumer products in the United States. Its GMPD segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. The Company connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| P/E RATIO: | PASS |
| REVENUE GROWTH IN RELATION TO EPS GROWTH: | FAIL |
| SALES GROWTH RATE: | PASS |
| CURRENT QUARTER EARNINGS: | PASS |
| QUARTERLY EARNINGS ONE YEAR AGO: | PASS |
| POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: | PASS |
| EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: | PASS |
| EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: | PASS |
| EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: | PASS |
| EARNINGS PERSISTENCE: | FAIL |
| LONG-TERM EPS GROWTH: | PASS |
| TOTAL DEBT/EQUITY RATIO: | FAIL |
| INSIDER TRANSACTIONS: | PASS |
Detailed Analysis of CARDINAL HEALTH INC
GE HEALTHCARE TECHNOLOGIES INC (GEHC) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 77% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| P/E RATIO: | PASS |
| REVENUE GROWTH IN RELATION TO EPS GROWTH: | PASS |
| SALES GROWTH RATE: | PASS |
| CURRENT QUARTER EARNINGS: | PASS |
| QUARTERLY EARNINGS ONE YEAR AGO: | PASS |
| POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: | PASS |
| EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: | PASS |
| EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: | PASS |
| EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: | PASS |
| EARNINGS PERSISTENCE: | FAIL |
| LONG-TERM EPS GROWTH: | FAIL |
| TOTAL DEBT/EQUITY RATIO: | FAIL |
| INSIDER TRANSACTIONS: | PASS |
Detailed Analysis of GE HEALTHCARE TECHNOLOGIES INC
CVS HEALTH CORP (CVS) is a large-cap value stock in the Retail (Drugs) industry. The rating according to our strategy based on Martin Zweig is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. The Health Care Benefits segment offers a range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, PDPs and Medicaid health care management services. The Health Services segment provides a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells an assortment of health and wellness products and general merchandise.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| P/E RATIO: | PASS |
| REVENUE GROWTH IN RELATION TO EPS GROWTH: | PASS |
| SALES GROWTH RATE: | PASS |
| CURRENT QUARTER EARNINGS: | PASS |
| QUARTERLY EARNINGS ONE YEAR AGO: | PASS |
| POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: | PASS |
| EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: | FAIL |
| EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: | PASS |
| EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: | PASS |
| EARNINGS PERSISTENCE: | FAIL |
| LONG-TERM EPS GROWTH: | FAIL |
| TOTAL DEBT/EQUITY RATIO: | PASS |
| INSIDER TRANSACTIONS: | PASS |
Detailed Analysis of CVS HEALTH CORP
UNITEDHEALTH GROUP INC (UNH) is a large-cap value stock in the Insurance (Accident & Health) industry. The rating according to our strategy based on Martin Zweig is 69% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: UnitedHealth Group Incorporated is a healthcare company. The Company operates two businesses, Optum and UnitedHealthcare. Optum serves the healthcare marketplace, including patients and consumers, payers, care providers, employers, governments and life sciences companies, through its Optum Health, Optum Insight and Optum Rx businesses. UnitedHealthcare offers a full range of health benefits, simplifying the healthcare experience and providing affordable solutions. The Companys segments include Optum Health, Optum Insight, Optum Rx and UnitedHealthcare. The UnitedHealthcare segment includes UnitedHealthcare Employer & Individual, which serves consumers and employers; UnitedHealthcare Medicare & Retirement delivers health and well-being benefits to seniors and other Medicare-eligible consumers; and UnitedHealthcare Community & State serves consumers who are economically disadvantaged, the medically underserved and those without the benefit of employer sponsored health benefits coverage.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| P/E RATIO: | PASS |
| REVENUE GROWTH IN RELATION TO EPS GROWTH: | PASS |
| SALES GROWTH RATE: | PASS |
| CURRENT QUARTER EARNINGS: | PASS |
| QUARTERLY EARNINGS ONE YEAR AGO: | FAIL |
| POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: | PASS |
| EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: | FAIL |
| EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: | PASS |
| EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: | PASS |
| EARNINGS PERSISTENCE: | FAIL |
| LONG-TERM EPS GROWTH: | FAIL |
| INSIDER TRANSACTIONS: | PASS |
Detailed Analysis of UNITEDHEALTH GROUP INC
THERMO FISHER SCIENTIFIC INC (TMO) is a large-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Martin Zweig is 62% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, the Company provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, the Company provides an offering of instruments and the supporting consumables, software and services that are used for a range of applications. The Companys Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
| P/E RATIO: | PASS |
| REVENUE GROWTH IN RELATION TO EPS GROWTH: | PASS |
| SALES GROWTH RATE: | FAIL |
| CURRENT QUARTER EARNINGS: | PASS |
| QUARTERLY EARNINGS ONE YEAR AGO: | PASS |
| POSITIVE EARNINGS GROWTH RATE FOR CURRENT QUARTER: | PASS |
| EARNINGS GROWTH RATE FOR THE PAST SEVERAL QUARTERS: | FAIL |
| EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN PRIOR 3 QUARTERS: | PASS |
| EPS GROWTH FOR CURRENT QUARTER MUST BE GREATER THAN THE HISTORICAL GROWTH RATE: | PASS |
| EARNINGS PERSISTENCE: | FAIL |
| LONG-TERM EPS GROWTH: | FAIL |
| TOTAL DEBT/EQUITY RATIO: | FAIL |
| INSIDER TRANSACTIONS: | PASS |
Detailed Analysis of THERMO FISHER SCIENTIFIC INC
About Martin Zweig: During the 15 years that it was monitored, Zweig's stock recommendation newsletter returned an average of 15.9 percent per year, during which time it was ranked number one based on risk-adjusted returns by Hulbert Financial Digest. Zweig has managed both mutual and hedge funds during his career, and he's put the fortune he's compiled to some interesting uses. He has owned what Forbes reported was the most expensive apartment in New York, a $70 million penthouse that sits atop Manhattan's Pierre Hotel, and he is a collector of all sorts of pop culture and historical memorabilia -- among his purchases are the gun used by Clint Eastwood in "Dirty Harry", a stock certificate signed by Commodore Vanderbilt, and even two old-fashioned gas pumps similar to those he'd seen at a nearby gas station while growing up in Cleveland, according to published reports.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
